NeuroPace, Inc. Form 10-K Summary
Business context and reporting period
NeuroPace filed an Annual Report on Form 10-K for the fiscal year ended December 31, 2022. The filing is annual rather than a standalone fourth-quarter report, although it includes fourth-quarter developments. NeuroPace is a commercial-stage medical device company focused on its RNS System, a brain-responsive neuromodulation device indicated in the United States for adults with drug-resistant focal epilepsy. The company markets primarily through approximately 200 Level 4 comprehensive epilepsy centers and generated all reported revenue in the United States.
More than 4,000 patients had received the RNS System by year-end 2022. The company had 167 employees and operates manufacturing and distribution from its approximately 53,000-square-foot Mountain View, California facility.
Key financial metrics
| Metric | 2022 | 2021 | Change |
|---|---|---|---|
| Revenue | $45.5 million | $45.2 million | Up 1% |
| Gross profit | $32.5 million | $33.4 million | Down 3% |
| Gross margin | 71.4% | 74.0% | Down 2.6 percentage points |
| Research and development expense | $21.9 million | $18.2 million | Up 21% |
| Selling, general and administrative expense | $51.3 million | $39.0 million | Up 32% |
| Loss from operations | $40.8 million | $23.7 million | Loss increased 72% |
| Net loss | $47.1 million | $36.1 million | Loss increased 30% |
| Net loss per share | $1.91 | $2.17 | Improved on a per-share basis due primarily to higher share count |
| Net cash used in operating activities | $36.9 million | $24.6 million | Use increased $12.3 million |
Revenue comprised $35.7 million from initial implants, $8.2 million from replacement implants and $1.6 million from DIXI Medical products. Initial implant revenue increased 6%, while replacement implant revenue declined 29% as the newer RNS device has a battery life of nearly 11 years. DIXI Medical revenue began in the fourth quarter of 2022.
At December 31, 2022, cash, cash equivalents and short-term investments totaled $77.4 million, compared with $115.6 million at December 31, 2021. Cash and cash equivalents alone were $6.6 million. Current liabilities were $11.0 million, total assets were $114.1 million and total stockholders' equity was $34.8 million. The company had an accumulated deficit of $470.9 million.
Net cash provided by investing activities was $23.8 million, primarily from $24.4 million of short-term investment sales. Financing activities provided $0.5 million. Cash, cash equivalents and restricted cash declined by $12.6 million during the year.
Debt, liquidity and capital resources
Long-term debt, net of discount and issuance costs, was $52.9 million at year-end, compared with $49.8 million in 2021. The term loan has a stated interest rate of 12.5% for 2022, is secured by substantially all company assets including intellectual property, and had an annual effective interest rate of 15.68% at year-end. The company capitalized $1.9 million of paid-in-kind interest during 2022.
The term loan was interest-only through September 30, 2025, with a $62.1 million contractual payment shown for 2025, including principal and related amounts. The loan includes minimum annual revenue and minimum cash covenants. The company reported compliance with all covenants at December 31, 2022. In February 2023, the loan was amended to reduce the 2023 minimum annual revenue covenant to $45.0 million, permit DIXI revenue to count toward the covenant and increase the annual interest rate to 13.5% effective January 1, 2023.
Management believes existing cash, cash equivalents and short-term investments will fund operations for at least 12 months from issuance of the financial statements. However, management cautions that the estimate depends on assumptions that may prove incorrect, and additional equity or debt financing may be required. The company filed a shelf registration for up to $150.0 million, including a $50.0 million at-the-market program, but had not sold securities under either program through year-end.
Material changes versus the prior comparable period
- Revenue was broadly flat, increasing $0.3 million, as higher initial implant and DIXI sales offset lower replacement implant revenue.
- Gross margin declined from 74.0% to 71.4%, primarily because of lower production volume, higher fixed costs per unit and the lower margin of DIXI products.
- Research and development expense increased $3.7 million, driven by additional personnel, product development and clinical-study spending.
- SG&A increased $12.4 million, reflecting expanded personnel and sales force costs, public-company expenses, marketing and field support, and DIXI launch costs.
- Operating cash use increased materially, from $24.6 million to $36.9 million.
- Cash and short-term investments decreased by $38.2 million, while debt increased by $3.1 million.
- The company adopted lease accounting guidance effective January 1, 2022, recognizing operating lease right-of-use assets and liabilities without an impact on reported operations or cash flows.
- The company extended its Mountain View facility lease through June 2030, with $23.0 million of undiscounted future minimum lease payments at year-end.
- NeuroPace paid DIXI Medical $2.0 million in the fourth quarter of 2022 for ongoing commercial support and expects to pay $1.25 million in each of the fourth quarters of 2023 and 2024.
- A previously identified material weakness in internal control over financial reporting was reported as remediated by March 31, 2022. Management concluded disclosure controls and internal control over financial reporting were effective at December 31, 2022; the auditor was not required to attest to internal control effectiveness.
Guidance, outlook, management commentary and risks
Management expects continued net losses and negative operating cash flow for the next several years while it invests in sales and marketing, clinical studies, regulatory activities, product enhancements and public-company infrastructure. Growth priorities include increasing utilization within existing epilepsy centers, adding implanting centers, expanding referral pathways, leveraging the DIXI relationship, and pursuing FDA label expansion for generalized epilepsy and patients ages 12 to 17.
The RNS System is not currently approved for generalized epilepsy, patients under 18 or markets outside the United States. Clinical studies for adolescent and generalized epilepsy indications were enrolling, but expanded commercialization remains contingent on clinical results and FDA approval.
COVID-19 continued to affect procedure volumes, hospital staffing, epilepsy diagnostic evaluations and the patient pipeline, although management stated that its revenue impact had diminished by the second half of 2022. Other material risks include the company's history of losses, high cash burn, substantial secured debt, revenue-covenant compliance, potential need for additional capital, dependence on single-source suppliers, manufacturing concentration in one facility, reimbursement changes, competition from VNS and DBS, regulatory and clinical-study uncertainty, product liability, cybersecurity and health-data privacy exposure, intellectual property disputes, and macroeconomic and supply-chain disruption.
The filing states that no material legal proceedings or contingent liabilities required accrual at December 31, 2022. It also states that the company had no customer representing 10% or more of revenue or accounts receivable.
Most important facts for investors to verify
- Whether revenue growth accelerates sufficiently to offset rising operating expenses and support the amended $45.0 million 2023 revenue covenant.
- The pace of initial implants, utilization at Level 4 centers and the effect of the longer replacement cycle on recurring revenue.
- DIXI Medical revenue, gross margin, required purchase commitments and the return on the $4.5 million commercial-support payments.
- Cash burn, liquidity runway, debt-service requirements and the ability to refinance or repay the term loan in 2025.
- Progress, enrollment, safety results and FDA outcomes for adolescent and generalized-epilepsy studies.
- Whether gross margin recovers as production volume increases and product mix improves.
- Exposure to single-source suppliers, manufacturing interruptions, reimbursement reductions and hospital procedure delays.
- Future equity or debt financing needs and potential dilution under the shelf and ATM registration statements.
- Ongoing effectiveness of internal controls following remediation of the 2021 material weakness.